Ron Blankstein retweeted
In med school, I founded the PowerPoint Academy and taught students/professors/professionals to give effective academic presentations.
So yes, I feel conflicted about the boom of AI-generated slides at conferences.
8 tips so your AI slides don’t look like everyone else’s 🧵
#AHA2026 #PanelDiscussion @Heart_SCCT Session
Great talks and panel discussion on plaque imaging, FFR-CT, and CAC @MichaelJBlaha @CardiacCTGuy #CaptionThis
Such a well deserved #AHA26 award for @emilyswlau -- recipient of the Nanette K. Wagner Research Goes Red Award! @MassGenBrigham
Ron Blankstein retweeted
ZEUS trial: Ziltivekimab 15 mg SC once-monthly yielded comparable 3-point MACE incidence rate vs. placebo (6.7 vs. 6.8 per 100 person-years) over a median on-treatment period of 33 months in high-risk patients with ASCVD and CKD, showing no significant clinical benefit.
Download slides here: clinicaltrialresults.org/wp-…
"A Needle Full of Haystacks: Using AI to Screen and Manage Disease" #AHA2026
🔑 discussion points: validation and operationalization of AI models. Augmenting (not replacing) physicians. Opportunities and pitfalls for improving prevention, detection, and management of CVD
Ron Blankstein retweeted
Atherosclerosis across the Adult Lifespan — A Call to Act from REACT | New England Journal of Medicine nejm.org/doi/10.1056/NEJMe26… - Congratulations to my long-time & most favorite collaborator Professor @WendyPost9 & the Dak Professor of 🫀@dramitkhera @CiccaroneCenter @hopkinsheart
Ron Blankstein retweeted
Important announcement!
scct.org/page/EICcall2026?_z…
Ron Blankstein retweeted
Cover Story | Inflammation as a Treatable Target: The Rise of Cardio-Immunology - American College of Cardiology acc.org/Latest-in-Cardiology…
Inspiring story @UVACVRC
Presented at #TCT2026:
In a randomized trial, CCTA-guided PCI with structured preprocedural planning and intraprocedural guidance was noninferior to intravascular ultrasound–guided PCI with respect to target-vessel failure at 12 months. Full P4 trial results: nej.md/48jfVly
@crfheart

ALT A graph from the Original Article "Coronary CT Angiography versus Intravascular Ultrasound Guidance for PCI." The trial name, P4, is in parentheses after the title. The graph shows the cumulative incidence of target-vessel failure (primary end point), defined as a composite of death from cardiac causes, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization, at 12 months. The trial results are being presented at the Transcatheter Cardiovascular Therapeutics 2026 Conference. The logo of the New England Journal of Medicine is at the bottom.
Ron Blankstein retweeted
P4 is out: CT-guided PCI was noninferior to IVUS-guided PCI for 12-mo TVF (4.1% vs 4.6%; n=1,105, 23 centers). Procedures were 17 min shorter with less contrast and radiation, and safety was similar. CT moves from gatekeeper to procedural tool. #TCT2026 @ColletCarlos
Ron Blankstein retweeted
What is HALT? How is it different from valve thrombosis or pannus?
Confused by the terminology? Join us at #TCT2026 session in complex case theatre 2 as we decode the differences, explore key multimodality imaging insights, and discuss treatment strategies through exciting cases
From imaging to management—let’s clear the confusion! 🫀
Ron Blankstein retweeted
The present of advanced submillimetric imaging is PHOTON COUNTING CT.
This is today not tomorrow, in 5 or 10 years.
This is a new imaging modality.
It's a new approach, a new semeiology, a new opportunity for better outcomes and more personalized care.
And tomorrow PCCT will also provide molecular imaging.
Ron Blankstein retweeted
.@WilliamZoghbi What an honor to host you @Lahey_Clinic for Cardiology and Medicine Grand Rounds! You are an inspiration! Thank you for so many educational and life lessons! @HMethodistCV
Ron Blankstein retweeted
In our new @masala_study analysis @JACCJournals, Lp(a) levels vary among disaggregated South Asian groups, but the association between Lp(a) levels and outcomes does not.
@UCSDCardiology @UCSDCardFellows
sciencedirect.com/science/ar…
Ron Blankstein retweeted
A prevention conundrum:
- LDL-C lowering is prioritized after an ASCVD event because near-term absolute risk is high.
- Yet relative benefit is greater before a first event and at younger ages.
sciencedirect.com/science/ar… (Burger PM et al Atherosclerosis 2024)
We need to keep moving toward improving high lifetime-risk identification before the disease declares itself.
In CV imaging, it is essential to ensure that our reports are clinically meaningful, concise, and actionable.
As #CCTA evolves, so must our reports. In this editorial -- accompanying 2026 @Heart_SCCT interpretation and reporting guideline -- we highlight recent changes and future opportunities.
👏 @AnamWaheed05 tinyurl.com/4z6987ar
Thanks @CMEINDIA1 for featuring our article and spreading the #prevention mantra @ACCinTouch @EugeniaGianos @rblument1
Coronary Calcium Is Changing the Rules of Lipid Management: Treat the Plaque, Not Just the Risk Score!
Article: Imaging Guided Treatment of Subclinical Atherosclerosis—We've Come a Long Way!
Authors: Eugenia Gianos, MD, and Ron Blankstein, MD.
Journal: Journal of Clinical Lipidology, 2026;20:11–14.
12 Clinically Important Pearls
1\. Risk scores alone are no longer the whole story. The 2026 ACC/AHA dyslipidemia guideline integrates PREVENT-ASCVD risk estimation, risk enhancers and selective coronary artery calcium (CAC) imaging to personalize lipid-lowering therapy.
2\. CAC scoring receives a Class I recommendation. In men aged ≥40 years and women aged ≥45 years with 10-year PREVENT-ASCVD risk of 3% to less than 10%, CAC scoring is recommended when the decision regarding lipid-lowering therapy remains uncertain.
3\. CAC = 0 does not mean zero risk. Statin deferral may be considered in selected individuals, but should not be automatic in patients with diabetes, familial hypercholesterolemia, active smoking or a strong family history of premature ASCVD.
4\. CAC 1–99: Consider moderate-intensity statin therapy, particularly when CAC is ≥75th percentile. The suggested LDL-C goal is below 100 mg/dL.
5\. CAC 100–299: Initiate LDL-C-lowering therapy, targeting LDL-C below 70 mg/dL.
6\. CAC 300–999: Target LDL-C below 70 mg/dL. A more intensive LDL-C goal below 55 mg/dL may be considered, particularly in selected high-risk patients.
7\. CAC ≥1000: Extensive coronary atherosclerosis warrants intensive lipid lowering, targeting LDL-C below 55 mg/dL, with an optional ApoB goal below 55 mg/dL.
8\. CAC may underestimate plaque burden. Patients with diabetes, HIV, inflammatory disorders or markedly elevated Lp(a) may have substantial noncalcified coronary plaque. Selective coronary CT angiography carries a Class IIb recommendation.
9\. Never ignore incidental CAC on chest CT. Coronary calcification detected during CT examinations for noncardiac indications provides valuable cardiovascular risk information. Moderate-to-severe incidental CAC supports considering moderate- to high-intensity statin therapy with an LDL-C goal below 70 mg/dL.
10\. The VESALIUS-CV trial strengthens primary prevention in selected high-risk patients. Evolocumab demonstrated cardiovascular benefit in patients with high-risk diabetes or atherosclerosis without previous myocardial infarction or stroke.
11\. Lower for longer is becoming increasingly important. Earlier and sustained reduction in LDL-C may reduce cumulative exposure to atherogenic lipoproteins and potentially prevent the development or progression of subclinical atherosclerosis.
12\. CAC is a decision-making tool, not a universal screening test. Patients who already have a clear indication for lipid-lowering treatment should not have therapy delayed merely to obtain a CAC score.
CME INDIA – Take-Home Message
The absence of cardiovascular symptoms does not imply the absence of coronary atherosclerosis.
The emerging approach is to combine clinical risk estimation with selective plaque imaging, identify subclinical disease earlier and match LDL-C targets to atherosclerotic burden.
Remember: CAC = 0 is not a lifetime guarantee of cardiovascular protection, while CAC ≥300 identifies substantial subclinical coronary disease that deserves serious consideration of intensive lipid lowering.
doi.org/10.1016/j.jacl.2026.…
CME INDIA – Learning Today, Improving Patient Care Tomorrow.
Ron Blankstein retweeted
How can the new FFR-CT consensus recommendations translate into everyday clinical practice? Join SCCT/ @SCAI experts for practical guidance on patient selection, image acquisition and standardized reporting.
Register: ow.ly/Hz7F50ZYcHX
Panel #3 @Heart_SCCT #PreventionSymposium discussing how to manage pts with high Lp(a), extensive CAC, diabetes, and more.
How do you manage a patient wtih very high Lp(a) but mild CAC. Great insights by @ArthurShiyovich at our 9th annual #PreventionSymposium




































